Auxvasse, Mo. — Sinclair Research, one of the leading providers of nonclinical research services, has named Ian Vanterpool as Vice President of Operations. In this newly created role, Vanterpool will have overall responsibility for driving operational excellence and sustainable growth of Sinclair’s toxicology and efficacy operations and fostering positive relationships with current and new customers.
“My key focus is to ensure Sinclair Research’s operations are scaleable and sustainable as we support the research programs of our growing customer base,” Vanterpool said. “Human capital remains a critical part of our growth strategy and equally important is our investment in training, compliance and operational excellence. We will continue our pursuit of industry best practice with an emphasis on quality and enthusiasm to for the work we do for our sponsors every day.”
A results-orientated operational leader whose diverse background in nonclinical research operations and executive management in the CRO industry make him a perfect match for his role at Sinclair, Ian brings extensive experience in global R&D organizations and the development of novel compounds, devices and diagnostics. Vanterpool joins Sinclair Research from Covance (formerly Envigo) where he served 23 years in a variety of operational leadership roles including Training and Compliance Manager, Divisional Manager, Vice President of Toxicology Operations and General Manager, and was responsible for the overall leadership, financial performance and direction of complex operational divisions supporting research programs for large and small biopharmaceutical companies.
“Ian is a gem in the nonclinical CRO industry,” said Guy Bouchard, DVM, CEO of Sinclair Research. “He has a keen sense of what drives organizational success and brings a decades-long successful track record of driving and implementing enhancements that drive operational efficiency for staff and deliver real value to our customers as they seek a high quality CRO that is focused on their success first and foremost. I’m excited for the transformational impact Ian will have at Sinclair Research.”
About Sinclair Research
Sinclair Research, a nonclinical contract research organization (CRO), offers animal efficacy models, pharmacokinetics/pharmacodynamics evaluation, and IND-enabling toxicology and safety pharmacology research capabilities to support biopharmaceutical, animal health and medical device development programs. Sinclair is experienced in all research models and is the leading expert in miniature swine research. Built on more than 50 years of experience, Sinclair has emerged as a leader in diabetes, dermal, otic and animal health research services with streamlined quality systems supporting both VICH and GLP-compliant studies and SEND reporting with no backlog.
For media inquiries, please contact: